Fiona Havers, who oversees CDC respiratory virus data, told colleagues she no longer had confidence the data would be used ...

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.